Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TORNALATE vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Bronchodilator for asthma,Chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Hepatic via sulfation and glucuronidation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 70% bound to plasma proteins, primarily albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution is approximately 1.4-2.1 L/kg, indicating extensive tissue distribution, particularly to the lungs.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Inhalation: systemic bioavailability is about 20% due to pulmonary deposition and subsequent absorption; oral bioavailability is low (<5%) due to first-pass metabolism.
Oral: 40-50%; Inhalation: 20-30%
No dose adjustment required for renal impairment.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No specific guidelines; caution in severe hepatic impairment due to lack of data.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not approved for pediatric use.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Use with caution; initiate at lower end of dosing range due to potential for increased sensitivity.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None
No FDA black box warning.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias),Hypokalemia,Immediate hypersensitivity reactions
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to TORNALATE or any component
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No known food interactions. Avoid excessive caffeine as it may potentiate stimulant effects.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; second/third trimester: may cause fetal tachycardia, hypoglycemia, and hyperglycemia due to beta agonist activity. Risk of preterm labor and low birth weight with chronic use. Overall, consider risk-benefit; not a major teratogen.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excretion in human milk is unknown; M/P ratio not established. Beta-2 agonists likely present in low amounts. Consider that maternal asthma control is important; benefit of breastfeeding likely outweighs minimal risk if mother is stable. Monitor infant for irritability, tachycardia, or feeding difficulties.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No dose adjustment required for pregnancy per se. However, pregnancy may alter asthma severity; adjust dose to achieve optimal control. Monitoring for maternal tachycardia or hypokalemia may necessitate dose reduction. No established pregnancy-specific pharmacokinetic changes requiring routine dose adjustment.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
TORNALATE (bitolterol mesylate) is a selective beta-2 adrenergic agonist used as a bronchodilator. It has a faster onset than albuterol (within 3–5 minutes) but a shorter duration (3–5 hours). It is primarily indicated for acute bronchospasm in asthma or COPD. Caution in patients with cardiovascular disease, as it may cause tachycardia or arrhythmias. Not a first-line agent due to availability of longer-acting alternatives. Monitor for paradoxical bronchospasm and excessive dosing.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Use only as directed for acute symptoms; do not exceed prescribed dose.,Rinse mouth after inhalation to prevent oral candidiasis.,Seek immediate medical help if symptoms worsen or you need more inhalations than usual.,Inform your doctor about any heart conditions, high blood pressure, or seizures.,Report side effects like chest pain, rapid heartbeat, or worsening breathing.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TORNALATE vs AEROLATE III, answered by our medical review team.
TORNALATE is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TORNALATE and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TORNALATE is: 2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TORNALATE and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TORNALATE is classified as Category C. TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no kno. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.